Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0480-0389 A/mL · 1 trial · 1 indication
h\*nmol/L
h\*nmol/L
| Arm | Type | Description |
|---|---|---|
| NNC0480-0389 + semaglutide(co-formulation)and placebo | EXPERIMENTAL | Sequence A: The participants will be administered a single subcutanous (s.c.) dose of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate dosing visits separated by at least 8 weeks. The two drugs will be administered as a co-formulation by a single injection and a placebo injection |
| NNC0480-0389 + semaglutide (separate injections) | ACTIVE_COMPARATOR | Sequence B: The participants will be administered 0.5 mg semaglutide and 5 mg NNC0480 0389 as an subcutaneus injection (s.c) on two separate dosing visits separated by at least 8 weeks. The two drugs will be administered as two separate injections. |
| Name | Type | Description |
|---|---|---|
| Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL | DRUG | Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks. |
| semaglutide 1.34 mg/mL (placebo) | DRUG | Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks. |
| Semaglutide 1.34 mg/mL | DRUG | The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks. |
| NNC0480-0389 A 10 mg/mL | DRUG | The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks. |
Inclusion Criteria: * Male or female of non-childbearing potential (NCBP), aged 18-55 years (both inclusive) at the time of signing informed consent. * Body mass index (BMI) between 20.0 and 29.9 kg/m\^2 (both inclusive). Exclusion Criteria: * Any disorder which in the investigator's opinion migh...
NNC0480-0389 A/mL is an investigational small molecule being developed by Novo Nordisk for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 1 clinical development, meaning it is still being studied and has not been approved for use.
NNC0480-0389 A/mL is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVO. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics.
NNC0480-0389 A/mL is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and how it behaves in the body.
NNC0480-0389 A/mL has one completed Phase 1 clinical trial, identified as NCT05046873. This study, conducted in Germany, enrolled 16 healthy participants to investigate blood levels of semaglutide and NNC0480-0389 when given in the same injection or in two separate injections.
NNC0480-0389 A/mL is not the same as semaglutide. It is a separate investigational compound being studied by Novo Nordisk. A clinical trial (NCT05046873) compared the blood levels of both drugs when administered together or separately, indicating they are distinct molecules.